NOTE
10 - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS
Basic
net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted
average number of common shares outstanding during the period. All outstanding stock options and warrants for the six months ended June
30, 2026, and 2025 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive
for all periods presented.
The
following table sets forth the computation of the net loss per share for the period presented:
SCHEDULE OF NET LOSS PER SHARE
| | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | |
| | |
2026 | | |
2025 | |
| Numerator: | |
$ | | | |
$ | | |
| Net loss | |
| (4,899 | ) | |
| (3,971 | ) |
| Dividend on Series X Preferred Stock | |
| (606 | ) | |
| (344 | ) |
| Dividend on Series H Preferred Stock | |
| (224 | ) | |
| - | |
| Deemed dividend for down round on Series H Preferred Stock (See note 7) | |
| (6,583 | ) | |
| - | |
| Deemed contribution on extinguishment of Series X Preferred Stock | |
| 148 | | |
| 3,815 | |
| Deemed dividend on modification of Series H Preferred Stock (See note 7) | |
| - | | |
| - | |
| Net loss available to common stockholders | |
$ | (12,164 | ) | |
$ | (500 | ) |
| | |
2026 | | |
2025 | |
| | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | |
| Numerator: | |
$ | | | |
$ | | |
| Net loss | |
| (8,721 | ) | |
| (5,843 | ) |
| Dividend on Series X Preferred Stock | |
| (1,229 | ) | |
| (344 | ) |
| Dividend on Series H Preferred Stock | |
| (461 | ) | |
| - | |
| Deemed dividend for down round on Series H Preferred Stock (See note 7) | |
| (23,556 | ) | |
| - | |
| Deemed contribution on extinguishment of Series X Preferred Stock | |
| 279 | | |
| 3,815 | |
| Deemed dividend on modification of Series H Preferred Stock (See note 7) | |
| (1,097 | ) | |
| - | |
| Net loss available to common stockholders | |
$ | (34,785 | ) | |
$ | (2,372 | ) |
The
following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:
SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE
| | |
June 30, 2026 | | |
June 30, 2025 | |
| Stock options - employee and non-employee | |
$ | 4,411 | | |
$ | 4,411 | |
| Warrants | |
| 1,145,436 | | |
| 514,006 | |
| Total | |
$ | 1,149,847 | | |
$ | 518,417 | |
The
diluted loss per share equals basic loss per share for the six months ended June 30, 2026, and 2025 because the Company had a net loss
and the impact of the assumed exercise of stock options and warrants would have been anti-dilutive.
ENVUE MEDICAL, INC.
Notes to the Interim Condensed Consolidated Financial
Statements (Unaudited)
(Amounts in thousands except share and per share
data)
|